CompletedPhase 3NCT02469857
Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections
Studying Necrotizing fasciitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Atox Bio Ltd
- Principal Investigator
- Wayne M Dankner, MD, MDAtox Bio Ltd
- Intervention
- AB103 0.5 mg/kg(drug)
- Enrollment
- 290 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2015 – 2019
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Maricopa Medical Center, Phoenix, Arizona, United States
- Banner University Medical Center, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Los Angeles, California, United States
- University of California, Davis Medical Center, Sacramento, California, United States
- UCSD Medical Center, San Diego, California, United States
- UCH-Memorial Health System, Colorado Springs, Colorado, United States
- University of Colorado Hospital, Denver, Colorado, United States
- Yale New Haven Hospital, New Haven, Connecticut, United States
- Washington Hospital Center, Washington D.C., District of Columbia, United States
- UF Health Shands Hospital, Gainesville, Florida, United States
- Ryder Trauma Center/Jackson Memorial Hospital, Miami, Florida, United States
- Emory University at Grady Memorial Hospital, Atlanta, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Biomedical Advanced Research and Development Authority
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02469857 on ClinicalTrials.govOther trials for Necrotizing fasciitis
Additional recruiting or active studies for the same condition.